Nasdaq:US$13.33 (-0.09) | HKEX:HK$20.30 (-0.52) | AIM:£1.96 (-0.06)
新闻中心及演示文稿
上一篇文章   |   下一篇文章
演示文稿, 科学出版物 | 2013-04-06

AACR 2013: Synergistic effect of c-Met inhibitor savolitinib in combination with EGFR inhibitor Gefitinib on EGFR-TKI resistant NSCLC model HCC827C4R harboring acquired Met gene amplification